Abstract: A salt serving as an Akt inhibitor and a crystal thereof, specifically related to a salt of the compound of formula (I) and a crystal thereof.
Type:
Grant
Filed:
December 12, 2018
Date of Patent:
March 1, 2022
Assignee:
HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
Inventors:
Gang Li, Lun Lu, Qingqing Lu, Lihong Hu, Charles Z. Ding
Abstract: Disclosed in the present invention are a salt form and a crystal form serving as FGFR and VEGFR inhibitor compounds, a preparation method therefor, and medical uses thereof.
Abstract: Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
June 13, 2017
Date of Patent:
May 19, 2020
Assignee:
HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
Inventors:
Lun Lu, Zhibo Zhang, Gang Li, Lihong Hu, Charles Z. Ding, Shuhui Chen
Abstract: FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.